A PKC-beta inhibitor prompts the HUVECs apoptosis-induced by advanced glycation end products

Pharmazie

Volumn 66, Issue 11, 2011, Pages 881-887

  Wang, Shan Shan ^a   Xu, You Hua ^a   Feng, Liang ^a   Zhu, Quan ^a,b   He, Bao ^b  

^a MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^b Institute of Consun Co for Chinese Medicine in Kidney Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; ADVANCED GLYCATION END PRODUCT; ETHIDIUM BROMIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; RUBOXISTAURIN; STREPTAVIDIN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; COLORING AGENTS; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MALEIMIDES; MICROSCOPY, FLUORESCENCE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRAZOLIUM SALTS; THIAZOLES;

EID: 80053197060     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0861     Document Type: Article

References (30)

1. Antonsson B, Martinou JC (2000) The Bcl-2 protein family. Exp. Cell Res 256: 50-57. (Pubitemid 30211166)
2. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105: 816-822. (Pubitemid 34174921)
3. Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175. (Pubitemid 36231924)
4. Bursell SE, King GL (1999) Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract 45: 169-182.
5. Cai W, He JC, Zhu L, Lu C, Vlassara H (2006) Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad SciUSA103: 13801-13806. (Pubitemid 44413988)
6. Das Evcimen N, King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55: 498-510. (Pubitemid 46962309)
7. Frank RN (2002) Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitor. Am J Ophthalmol 133: 693-698.
8. Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331.
9. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D (2005) The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469. (Pubitemid 41161281)
10. Gutterman DD (2002) Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circ Res 90: 5-7.
11. Idris I, Donnelly R (2006) Protein kinase C beta inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab Vasc Dis Res 3: 172-178. (Pubitemid 44902483)
12. King H (1998) Global burden of diabetes, 1995-2005: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414 -1431.
13. Kowluru RA (2005) Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions. Life Sci 76: 1051-1060.
14. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115-126. (Pubitemid 27311249)
15. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376. (Pubitemid 36302216)
16. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 396: 580-584. (Pubitemid 28563719)
17. Noh H, King GL (2007) The role of protein kinase C activation in diabetic nephropathy. Kidney Int 106: 49-53.
18. Pecci A, Scholz A, Pelster D, Beato M (1997) Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. J Biol Chem 272: 1791-11798.
19. Scivittaro V, Ganz MB, Weiss MF (2000) AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278: 676-683.
20. Susnow N, Zeng L, Margineantu D, Hockenbery DM (2009) Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol 19: 42-49.
21. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S (2010) Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010: 792393.
22. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97: 238-243.
23. Xia L, Wang H, Munk S, Frecker H, Goldberg HJ, Fantus IG, Whiteside CI (2007) Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. Am J Physiol Endocrinol Metab 293: 1280-1288.
24. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL (1996) Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026. (Pubitemid 26376289)
25. Xu Y, Wang S, Feng L, Zhu Q, Xiang P, He B (2010) Blockade of PKC-beta protects HUVEC from advanced glycation end products induced inflammation. Int Immunopharmacol 11: 1552-1559.
26. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277: 20309-20315. (Pubitemid 34967325)
27. Yamagishi S (2008) Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease. Curr Pharm Des 14: 939.
28. Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59: 4413-4418. (Pubitemid 29418762)
29. Zhou YJ, Wang JH, Zhang J (2006) Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem Biophys Res Commun 344: 658-666.
30. Zoubin Alikhani, Mani Alikhani, Coy M. Boyd, Kiyoko Nagao, Philip C. Trackman, Dana T. Graves (2005) Advanced glycation endproducts enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem 280: 12087-12095.